ABOUT
About Medicinal Wolverine
An independent editorial project that reads the BPC-157 TB-500 research record one constituent at a time — what the studies show, where they stop, and exactly where regulated access stands.
What this site is
Medicinal Wolverine is an independent editorial project that publishes summaries of the peer-reviewed research literature on the BPC-157 TB-500 "Wolverine" blend and its two constituents. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science and the public FDA record.
The site exists because the blend is discussed far more than it is documented. "Wolverine" is a research-community pairing of two distinct peptides, and most of what circulates about it collapses two separate literatures into one set of confident claims. Our editorial choice is the opposite: read each constituent on its own channel, mark every finding with the peptide it belongs to, and keep the honest gaps — no combination trial, a fragment-versus-full-length identity caveat on TB-500, and a thin human record — visible rather than smoothed over.
What "medicinal" means here
The word "medicinal" in this domain is editorial framing, not a claim about services. It signals the register we read in — what the blend's constituents have been studied for in a research and clinical-science context, and where regulated medicinal access actually stands under the FDA's 503A compounding framework. It is a position the publisher occupies relative to the literature, not an offer of treatment, consultation, diagnosis, or prescription. Nothing on this site is a recommendation to use either peptide.
We describe what was administered to which species at which dose by which route, and we report the present-tense regulatory status from FDA sources. We do not recommend human doses, we do not name pharmacies or vendors, and we do not describe ways to obtain a restricted substance outside the lawful framework.
How we source
Every quantitative claim on this site maps to a numbered citation: a peer-reviewed study or review for the science, and an FDA page for the regulatory and access facts. Where the evidence is preclinical, we say so. Where a finding rests on full-length Thymosin Beta-4 rather than the TB-500 fragment, we say so. Where there is simply no data — combination efficacy, blend pharmacokinetics, long-term human safety — we say that too, because a marked gap is more useful than a confident guess.